RecruitingPhase 2NCT06397313

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

An Open-Label Clinical Trial of RVU120 as Monotherapy and in Combination With Ruxolitinib in Patients With Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Sponsor

Ryvu Therapeutics SA

Enrollment

230 participants

Start Date

Sep 19, 2024

Study Type

INTERVENTIONAL

Conditions

Myelofibrosis

Summary

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called RVU120 and a drug called Ruxolitinib for people with myelofibrosis. The study is currently recruiting participants at 18 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRVU120

RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

DRUGRuxolitinib

Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2

Locations(18)

Policlinico Sant'Orsola-Malpighi

Bologna, Italy

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Brescia, Italy

Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"

Catania, Italy

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l.

Meldola, Italy

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

Milan, Italy

Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej

Biała Podlaska, Poland

Szpital Uniwersytecki nr 2 im. dr Jana Biziela

Bydgoszcz, Poland

M2M Med. Sp. z o.o. Sp. j.

Chorzów, Poland

Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych Faz

Gdansk, Poland

Pratia Hematologia Sp. z o.o.

Katowice, Poland

Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej

Kielce, Poland

Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

Krakow, Poland

Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie

Lublin, Poland

Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu

Torun, Poland

Lux Med Onkologia Sp. z o.o.

Warsaw, Poland

Wojskowy Instytut Medyczny Państwowy Instytut Badawczy

Warsaw, Poland

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

Wroclaw, Poland

Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.

Zielona Góra, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06397313

Related Trials

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

NCT063454951 location

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT0532019828 locations

Haplo-HSCT for Myelofibrosis

NCT066743821 location

A Telehealth Advance Care Planning Intervention

NCT058758051 location

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161207 locations